Latest Insider Transactions at Genelux Corp (GNLX)
This section provides a real-time view of insider transactions for Genelux Corp (GNLX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GENELUX CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GENELUX CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 05
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
14,251
-0.49%
|
$356,275
$25.18 P/Share
|
|
Oct 03
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
75,690
-4.99%
|
$1,892,250
$25.49 P/Share
|
|
Sep 28
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
2,289
-0.15%
|
$54,936
$24.12 P/Share
|
|
Sep 27
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
11,257
-0.74%
|
$270,168
$24.47 P/Share
|
|
Sep 26
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
29,805
-0.64%
|
$685,515
$23.67 P/Share
|
|
Sep 26
2023
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
5,200
-1.58%
|
$119,600
$23.5 P/Share
|
|
Sep 26
2023
|
Tony Yu SVP, Clinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,200
+4.46%
|
$31,200
$6.0 P/Share
|
|
Sep 25
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
12,458
-0.2%
|
$323,908
$26.25 P/Share
|
|
Sep 22
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
9,042
-0.29%
|
$244,134
$27.32 P/Share
|
|
Sep 21
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
7,549
-0.24%
|
$211,372
$28.36 P/Share
|
|
Sep 20
2023
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
6,000
-5.35%
|
$162,000
$27.96 P/Share
|
|
Sep 20
2023
|
Tony Yu SVP, Clinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+5.08%
|
$36,000
$6.0 P/Share
|
|
Sep 20
2023
|
Sean Ryder General Counsel |
SELL
Open market or private sale
|
Direct |
10,000
-94.59%
|
$300,000
$30.0 P/Share
|
|
Sep 20
2023
|
Sean Ryder General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+48.61%
|
$60,000
$6.0 P/Share
|
|
Sep 19
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Direct |
32,167
-87.18%
|
$836,342
$26.68 P/Share
|
|
Sep 18
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
30,292
-57.23%
|
$696,716
$23.69 P/Share
|
|
Sep 18
2023
|
John Thomas Director |
SELL
Open market or private sale
|
Direct |
3,334
-0.7%
|
$80,016
$24.99 P/Share
|
|
Sep 15
2023
|
John Thomas Director |
SELL
Open market or private sale
|
Direct |
3,333
-0.35%
|
$73,326
$22.03 P/Share
|
|
Sep 15
2023
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
10,400
-4.57%
|
$218,400
$21.93 P/Share
|
|
Sep 15
2023
|
Tony Yu SVP, Clinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,400
+8.19%
|
$62,400
$6.0 P/Share
|
|
Sep 14
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
25,276
-23.52%
|
$556,072
$22.04 P/Share
|
|
Sep 13
2023
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
29,800
-21.92%
|
$625,800
$21.14 P/Share
|
|
Sep 13
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
19,032
-12.47%
|
$399,672
$21.79 P/Share
|
|
Sep 13
2023
|
John W Smither Director |
SELL
Open market or private sale
|
Direct |
900
-11.51%
|
$18,000
$20.78 P/Share
|
|
Sep 12
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
20,265
-10.63%
|
$445,830
$22.13 P/Share
|
|
Sep 11
2023
|
John W Smither Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,920
+46.95%
|
-
|
|
Sep 11
2023
|
John Thomas Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,460
+0.71%
|
-
|
|
Sep 11
2023
|
James L Tyree Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,460
+21.73%
|
-
|
|
Sep 11
2023
|
Mary Mirabelli Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,460
+43.69%
|
-
|
|
Sep 11
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
32,351
-12.9%
|
$679,371
$21.97 P/Share
|
|
Sep 11
2023
|
Caroline Jewett Head of Quality |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+48.62%
|
-
|
|
Sep 11
2023
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+45.32%
|
-
|
|
Sep 08
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
24,831
-5.54%
|
$571,113
$23.49 P/Share
|
|
Sep 07
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
12,446
-3.72%
|
$298,704
$24.73 P/Share
|
|
Aug 30
2023
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
19,800
-12.71%
|
$475,200
$24.7 P/Share
|
|
Aug 18
2023
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
3,265
-2.05%
|
$75,095
$23.73 P/Share
|
|
Aug 18
2023
|
Joseph Cappello Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
3,265
-36.28%
|
$75,095
$23.73 P/Share
|
|
Aug 18
2023
|
Sean Ryder General Counsel |
SELL
Open market or private sale
|
Direct |
328
-36.44%
|
$7,544
$23.73 P/Share
|
|
Aug 18
2023
|
Doug Samuelson Vice President, Finance |
SELL
Open market or private sale
|
Direct |
1,297
-36.03%
|
$29,831
$23.73 P/Share
|
|
Aug 18
2023
|
Ralph Smalling Head of Regulatory |
SELL
Open market or private sale
|
Direct |
935
-31.17%
|
$21,505
$23.73 P/Share
|
|
Aug 18
2023
|
Caroline Jewett Head of Quality |
SELL
Open market or private sale
|
Direct |
515
-31.21%
|
$11,845
$23.73 P/Share
|
|
Aug 18
2023
|
Thomas Zindrick President and CEO |
SELL
Open market or private sale
|
Direct |
8,349
-36.3%
|
$192,027
$23.73 P/Share
|
|
Feb 27
2023
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+50.0%
|
-
|
|
Feb 17
2023
|
Gabe Woodward Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+19.28%
|
-
|
|
Feb 17
2023
|
Mary Mirabelli Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+50.0%
|
-
|
|
Feb 17
2023
|
James L Tyree Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|
|
Feb 17
2023
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
900
+50.0%
|
-
|
|
Feb 17
2023
|
Qian Zhang Associate VP, Research |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+4.13%
|
-
|
|
Feb 17
2023
|
John Thomas Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+1.84%
|
-
|
|
Feb 17
2023
|
Joseph Cappello Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|